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techniques such as DTI to delineate tumour volume. <5% 
patients develop disease recurrence predominantly in the 
low-dose radiotherapy (<30 Gy) region. Identification and 
prediction of dosimetrically distinct patterns of treatment-
failure that can be correlated with specific molecular profiles 
may be useful to individualize and thereby, improve survival 
of glioblastoma. 
Reference:1. Stupp R, Hegi ME, Mason WP et al. Lancet 
Oncol. 2009; 10:459 
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Purpose/Objective: Analyze the toxicity of and response to 
carbon ion radiotherapy (CIRT) in patients diagnosed with 
malignant mucosal melanoma (MMM) in the upper 
aerodigestive tract of the head and neck area inoperable, 
with macroscopic residual/relapse after surgery or in patients 
that refused surgery. 
Materials and Methods: We analyzed data coming from 
patients with an MMM diagnosis in the head and neck area 
treated at CNAO from May 2013 to October 2014 with carbon 
ion radiotherapy at a total dose of 68,8 GyE in 16 fractions. 
The toxicity was evaluated in the scale CTCAE v.4.0 and the 
response to the disease with MRI every three months from 
CIRT. 
Results: We treated 8 patients (average age 72 years-old, 
range from 48 to 86) with MMM in the following areas: 
nasopharynx (1 patient), lacrimal duct (1 patient), nasal 
cavity (4 patients), mouth (1 patient), oropharynx (1 
patient). 3 patients were treated with macroscopic residual 
after surgery, 2 patients after post-surgical relapse with 
positive margins, 3 patients only with CIRT. Average GVT was 
31.47 cc (range 7.76-84.23 cc). 2 patients received systemic 
therapy pre-CIRT (1 out of 2 also post-CIRT). In the course of 
treatment, toxicity appeared acceptable (≤ G2 in 7 patients, 
G3 mucositis in 1 patient). The mean follow-up was 8 months 
(range 3-12). 3 months follow-up was available for 5 patients 
(1 patient completed CIRT one month ago, 2 patients died at 
2 and 3 months after CIRT for the progression of distant 
disease) and showed low grade acute toxicity (G0 in 4 
patients, G1 in 1 patient); at 3 months response evaluated 
with RECIST was CR in 2 patients and PR in 3 patients. 
Follow-up at the 6 months (available for 4 patients) 
confirmed low intermediate toxicity (G1 in all the patients), 
partial response (PR) in 3 patients and complete response 
(CR) in 1 patient. Follow-up at 9 months was available for 4 
patients, the highest toxicity was G2 in 1 patients, PR in 1 
patient and CR in 3 patients. Follow-up at 12 months was 
available only for 1 patient, with confirmed CR and toxicity 
G1. Progression disease took place in 2 patients, respectively 
at 0 and 1 months after CIRT (in both cases distant PD in 
absence of local PD). 
Conclusions: Recommended treatment for patients with MMM 
in the head and neck area is surgery followed by adjuvant 
radiotherapy. In the event of macroscopic residual or not 
resectable disease, preliminary results observed at CNAO 
confirm that CIRT guarantee good local control, allowing high 
dose on complex volume and in the proximity of critical 
organs with very low 
These data are preliminary; larger patient number and longer 
follow up are needed. 
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Purpose/Objective: Glioblastoma multiforme (GBM) is the 
most common and malignant brain tumor in adults. 
Aggressive multimodal treatment using surgery followed by 
radiotherapy and chemotherapy extends the median survival 
of GBM patients to approximately one year after diagnosis. 
Treatment is not curative because of the intrinsic and 
acquired radiation resistance of a subpopulation of tumor 
cells. Notch inhibition has been shown to impair the 
tumorigenic capacity of these cells as well as enhance their 
sensitivity towards radiation. Therefore, we investigated if a 
highly potent and clinically approved Notch pathway inhibitor 
improves tumor control when combined with radiotherapy 
and chemotherapy in an orthotopic GBM mouse model.  
Materials and Methods: To investigate combinations between 
standard of care treatment and Notch inhibitors, we used a 
three dimensional spheroid assay from commercially 
available and primary glioma cell lines in which spheroid 
volume growth delay can be quantitatively monitored in 
individual spheroids. In addition, we assessed the expression 
of the putative glioma stem cell marker CD133 performing 
flow cytometry. Furthermore, therapeutic efficacy was 
evaluated in an orthotopic glioma tumor model wherein 
tumor progression was evaluated using bioluminescence (BLI) 
and contrast-enhanced micro-computed tomography (CT) 
imaging and confirmed using histopathological analysis. 
Dedicated small animal treatment planning software (SmART-
Plan) was used to create irradiation plans to deliver a 
conformal dose of 8Gy to the tumor with minimal normal 
tissue exposure. A small animal precision irradiation platform 
(PXI, XRAD 225Cx, CT, USA) was used for micro-CT imaging 
and radiation delivery. 
Results: Notch blockade alone did not affect the sphere 
volume compared to control, whereas combination treatment 
with radiation resulted in a substantial spheroid growth delay 
(p=0.004). Radiation treatment enhanced the expression of 
the stem cell marker CD133, while Notch blockade reduced 
CD133 expression. We found a strong correlation between CT 
and BLI imaging of tumor growth in vivo (Pearson coefficient 
(r)=0.85, p=0.001). The potential of Notch inhibition 
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combined with precision radiotherapy and chemotherapy in 
our orthotopic GBM model is currently being evaluated.  
Conclusions: The results of this will be presented. 
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Purpose/Objective: To evaluate the impact of two TBI 
schedules on the risk of relapse and transplant-related 
mortality (TRM) in 61 patients with acute leukemia who 
received HLA matched T-cell depleted allogeneic 
hematopoietic stem cell transplantation (matched HSCT). 
Materials and Methods: 29 males and 32 females (median 
age 48 years; range 20-66) were enrolled from January 1999 
to October 2013. 41 (67.2 %) patients had acute myeloid 
leukemia (AML) and 20 (32.8%) acute lymphoid leukemia 
(ALL). 43 patients were in first complete remission (CR1), 8 
in CR2 and 10 had persistent disease. Patients in CR1 and CR2 
were analyzed as one group. Group 1 (31 patients) 
conditioning was a hyperfractionated schedule (HTBI) (1.2 Gy 
3 times a day for 4 days up to 14.4 Gy; lung dose 9 Gy) from 
day -10 to day -7. Group 2 (30 patients) conditioning was a 
single TBI (STBI) schedule (8 Gy, at a median dose-rate of 
10.7 cGy/min, lung dose 4 Gy) delivered on day -9. All 
patients received Thiotepa (10 mg/kg) and Fludarabine (160 
mg/m2 ) consecutively from day -6 to day -3 after HTBI and 
from day -8 to day -2 after STBI. Anti-thymocyte globulin 
(ATG) was administered to 27 patients to strengthen the 
immunosuppressive effect of the conditioning regimen. No 
immunosuppressive drug was administered post-transplant as 
prophylaxis for Graft versus Host Disease (GvHD). All patients 
received anti-bacterial, antifungal, antiviral, anti-
Pneumocystis prophylaxis.  
Results: Median follow-up was 63.53 months (range 2.53-
186.77). No patient rejected the transplant. Acute GvHD 
occurred in 11/61 patients (18%; 8 Grade I-II and 3 Grade III). 
Four were in the HTBI group and 7 in the STBI group; no cases 
of chronic GvHD were observed. Relapse developed in 18 
patients (29.5%). The 5-year probability of relapse was 28% 
(CI 95% 0.17-0.41). Univariate analysis showed disease 
impacted significantly on the cumulative incidence of relapse 
with AML relapsing less than ALL (p=0.035). Overall, HTBI 
tended to be better than STBI (p=0.11). Age, disease stage, 
ATG administration, GvHD did not impact upon the risk of 
relapse. The Fine and Gray model with disease and TBI as 
main factors confirmed the results of the univariate analysis. 
With a different parametrization an even lower risk of 
relapse in AML patients who received HTBI not STBI (p=0.015) 
was found. TRM occurred in 10 patients (16,39%, 4/31 after 
HTBI; 6/30 after STBI). Causes of death were infection in 8 
patients and GvHD in 2 patients. The 5-year probability of 
TRM was 18%. Univariate analysis showed age, disease and 
disease stage, ATG administration, TBI schedule, GvHD had 
no impact on TRM.  
Conclusions: In AML patients HTBI in the conditioning 
regimen for HLA matched T-depleted HSCT is more 
efficacious than STBI in reducing the risk of relapse. 
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Purpose/Objective: Even if brain cancer is a rare disease, its 
rising trend of the last three decades with its poor survival 
rate needs further analysis, possibly based on large 
randomized trials conducted on population-based data. 
Moreover, because of few available standard therapeutic 
strategies the identification of prognostic and predictive 
factors is a recent field of interest towards personalized 
treatments. The effort should be the storage of a large 
database coming from several datasets avoiding semantic 
difference and in concepts description through the adoption 
of a uniform language. Therefore our aim is to build a brain 
cancer ontology to standardize data, creating a consistent 
and specific large database in order to produce predictive 
models, useful to implement a Decision Support System 
(DSS).  
Materials and Methods: A multi-professional team, involving 
medical doctors, a mathematician and an engineer, was 
employed to design an ontology in which concepts and data 
related to brain cancer are standardized and organized in 
order to create a storage of knowledge and data. Three 
different levels of analysis were considered to classify the all 
concepts. Some of them are related to general information in 
common with other cancer types, others are brain cancer 
related. In a next step, 'atomic' data type (i.e. integer, real, 
datatime) or structured data type (i.e.: a DICOM file, an XML 
structure, etc...) were added in order to provide a range for 
the predicates. 
Results: More than 200 clinical, bio-molecular, 
neuropsychological and imaging features related to brain 
cancer were selected and classified according to three 
different levels. The first, the Registry level, includes general 
and epidemiological information as patient code, sex, age, 
gender, ethnicity, site and histology of the tumor, 
institution, the death and its cause. This level can probably 
be shared with ontologies related to other cancer sites. The 
second, the Procedure level, reports variables related to the 
muti-discipinary management of patients and brain cancer 
specific. It includes information about clinical presentation of 
the tumor, about surgery, radiotherapy or chemotherapy 
treatment, about outcomes evaluation and toxicity. We 
represented toxicities according to CTCAEv4 and RTOG scales 
and we provided also a description of therapeutic 
relationship between the two standards. The third is the 
Research level considering the elements useful for advanced 
